Skip to main content
. 2023 Dec 7;8(3):591–602. doi: 10.1182/bloodadvances.2023011721

Figure 3.

Figure 3.

Survival outcomes in the previously untreated AML cohort that received TAG-AZA-VEN. (A) OS probability by intention-to-treat analysis using the method of Kaplan-Meier for the 26 patients in the 1L AML TAG-AZA-VEN cohort. (B) PFS probability for the same cohort, calculated as in panel A.